News

Clive Dix talks Proactive London's Katie Pilbeam about their worldwide licensing deal with international drugs giant Sanofi worth up to €414mln.

The group will receive €7mln upfront, plus €11mln in pre-clinical payments.

The deal is for their oral IL-17A inhibitor programme, currently IL-17 monoclonal antibodies are administered by injection. Having an oral version represents a significant breakthrough.

12 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that its subsidiary, C4X Discovery Limited (“C4XD”, “C4X Discovery” or the “Company”), has signed an exclusive worldwide licensing agreement with Sanofi (NASD: SNY, PAR: SAN - "Sanofi "), worth up to €414 million, for C4XD’s oral pre-clinical IL-17A inhibitor programme.  Under the terms of the agreement, C4XD will receive an upfront payment of €7 million and could receive up to a further €407 million in potential development, regulatory and commercialisation milestones, of which €11 million is in pre-clinical milestones, in addition to single digit royalties.

A new collaboration between Sano Genetics and industry partners aims to accelerate drug and biomarker discovery in ulcerative colitis (UC), a form of Inflammatory Bowel Disease (IBD).

Craig Fox, Chief Scientific Officer, C4X Discovery, added: “Identifying the right drug target for the right patient is a major but challenging goal for drug discovery, particularly for diseases with significant pathophysiological heterogeneity such as ulcerative colitis.

“Our proprietary Taxonomy3 platform will analyse the datasets produced from this research to identify novel drug targets and patient subtypes of UC which may provide a powerful insight into discovering new treatments and enrichment strategies for clinical success.”

Tuesday, 19 January 2021

Press Release Result of AGM

19 January 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that at its Annual General Meeting, held virtually today at 2.00 pm, all resolutions were duly passed.

18 December 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that its annual report and accounts for the year ended 31 July 2020 has been published on the Company's website and is available to download from: www.c4xdiscovery.com.

Clive Dix talks to Proactive London about taking over as the interim chair of the UK Vaccine Taskforce following the departure of Kate Bingham.

Dix goes on to discuss how this appointment will impact C4X, explaining "if you look at what we've achieved at C4X in the last year, I don't think you'll see a blemish on that productivity".

Thursday, 10 December 2020

Press Release Full Year Results

10 December 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces its full year audited results for the year ended 31 July 2020.

C4XD's Clive Dix steps up as Interim Chair of UK Vaccine Taskforce

8 December 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, confirms that Clive Dix, Chief Executive Officer of C4XD has stepped into the role of Interim Chair of the UK Vaccine Taskforce, the group set up by the Government to lead UK efforts to find and manufacture a COVID-19 vaccine. The Government will set out arrangements for the long-term leadership of the Vaccine Taskforce shortly.